Executive record

Amy Trombly

Director at Sonoma Pharmaceuticals, Inc.

Follow
More
Challenge a Claim

Alpha ID: alpha:person:amy-tromblyVersion: public-0As of: 2026-09-29

Not yet claimed9 published Claims3 sources
  • Director

Key Claims

Biography

Ms. Trombly has been Chief Executive Officer of Sonoma Pharmaceuticals since September 2019. She counseled public companies for two decades in corporate and securities law and mergers and acquisitions, and owned and managed Trombly Business Law, PC from 2002 to 2022. She previously served as Vice President at State Street Bank and Special Counsel at the U.S. Securities and Exchange Commission.

Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.

Board service

Boards

Claims

Executive career

  1. Dates not publishedExecutive title: Chief Executive Officer · Organization not publishedSNOA DEF 14A director slate

Claims

Conflicts and accountability

Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.

Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.

Evidence, history and coverage

Additional published Claims

Published evidence records

3 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. SNOA DEF 14A director slate

    sec filing · Source published: Jul 11, 2025 · Retrieved: May 16, 2026

    Supports 7 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Board role: Board role: Director · Claim reviewed: May 16, 2026
    • Committee assignments: No committee assignment disclosed in the cited filing · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Executive company: Executive at Sonoma Pharmaceuticals, Inc. · Claim reviewed: May 16, 2026
    • Executive title: Executive title: Chief Executive Officer · Claim reviewed: May 16, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  2. Open source

    sec proxy · Source published: Jul 11, 2025 · Retrieved: Apr 28, 2026

    Supports 1 claim
    • Professional Role: Director at Sonoma Pharmaceuticals, Inc. · Claim reviewed: May 16, 2026

  3. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Sonoma Pharmaceuticals, Inc. · Claim reviewed: May 16, 2026